{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-043061","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2022-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.491391+00:00","generated_at":"2026-06-21T13:10:13.872752+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eterna Therapeutics raises $7.7M via private placement of units with warrants","bullets":["Offered 2,184,950 units at $3.53 each, each unit consisting of one share and two warrants exercisable at $3.28 per share for five-and-a-half years.","Insiders Chairman Charles Cherington and director Nicholas Singer participated on same terms as other investors.","Closing expected December 2, 2022; net proceeds to be used for general working capital.","Warrants exercisable six months after closing, with beneficial ownership limitations of 4.99% (adjustable to 9.99%).","Securities offered under Section 4(a)(2) and Regulation D; resale registration rights to be filed within 30 days of S-3 eligibility."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-043061","json":"https://secwatch.observer/filing/0001140361-22-043061.json","markdown":"https://secwatch.observer/filing/0001140361-22-043061.md","text":"https://secwatch.observer/filing/0001140361-22-043061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036122043061/0001140361-22-043061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036122043061/brhc10044682_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T13:10:13.872752+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3632c08058511d7aebc6e16aa912c3bdf30cc4d5","claim":"Ernexa Therapeutics Inc. entered into Securities Purchase Agreement with certain investors valued at approximately $ 7.7 million (effective 2022-11-23).","evidence_excerpt":"On November 23, 2022, Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain investors (the “ Purchasers ”) providing for the private placement (the “ Private Placement ”) to the Purchasers of an aggregate of 2,184,950 units (collectively, the “ Units ”), each Unit consisting of (i) one share of the Company’s common stock, par value $0.005 per share (“ Common Stock ”) and (ii) two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share (the “ Warrants ”), for an aggregate purchase price of approximately $ 7.7 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122043061/0001140361-22-043061-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"approximately $ 7.7 million"},{"label":"Effective","value":"2022-11-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}